Combined therapy of GABA with GLP-1 prevents onset of diabetes by promoting β-cell regeneration in mice

摘要

Preclinical studies have shown that both γ-aminobutyric acid (GABA) and glucagon-like peptide-1 (GLP-1) exert β-cell regenerative effects in diabetic models. To investigate whether the combined therapy of GABA and GLP-1 exerts superior therapeutic effects than their respective monotherapies in diabetic animals, we used the multiple low-dose STZ-induced β-cell injury model (MDSD) to test this hypothesis. Conclusions: GABA and GLP-1 monotherapies delay the onset of MDSD in mice, but the combined therapy of GAB A and GLP-1 had superior therapeutic effects, likely due to the enhanced β-cell proliferation and decreased β-cell apoptosis. Both GABA and sitagliptin are oral drug preparations; our findings suggest that the combined therapy of GABA and sitagliptin is clinically relevant for treating patients with T1D.